

Clinical Trial Protocol

Iranian Registry of Clinical Trials

26 Jun 2026

A comparative study of the effect of two doses of sufentanil continuous infusion on changes in heart rate and blood pressure after laryngoscopy and tracheal intubation.

Protocol summary

Study aim

Determining and comparing the effect of two-dose sufentanil continuous infusion on changes in heart rate and blood pressure after laryngoscopy and tracheal intubation.

Design

A randomized, triple-blinding clinical trial, with parallel groups, Phase 3 on 90 patients

Settings and conduct

In this three-blind randomized clinical trial study, 90 eligible patients referred to Al-Zahra Hospital in Isfahan will be included in the study and will be randomly divided into 3 groups. During induction of anesthesia, sufentanil with a dose of 0.1 µg/kg, 0.2 µg/kg, and normal saline will be prescribed in three groups, respectively. The intervention will be performed in such a way that the patient, the researcher, and the statistical analyst will have no knowledge of the type of intervention. Then the hemodynamic parameters of patients will be evaluated and compared among the three groups.

Participants/Inclusion and exclusion criteria

The criteria for inclusion in the study include the age group of 18 to 65 years, having an American Association of Anesthesiologists (ASA) I, and requiring tracheal intubation for general anesthesia. Exclusion criteria include having Comorbidity (such as heart failure, respiratory, liver, kidney failure, and airway malformations), and addiction.

Intervention groups

Intervention group 1: In this group, anesthesia is induced within 60 seconds using sodium thiopental 5 mg/kg, lidocaine 1.5 mg/kg, atracurium 0.6 mg/kg, and sufentanil with a dose of 0.1 µg/kg. The second intervention group: in this group, in addition to the drugs of the first group, sufentanil is infused at a dose of 0.2 µg/kg within 60 seconds. Control group: in this group, in addition to the drugs of the first group, normal saline is

prescribed instead of sufentanil.

Main outcome variables

Systolic blood pressure, diastolic blood pressure, heart rate, oxygen saturation(Spo2)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200825048515N62**

Registration date: **2022-11-06, 1401/08/15**

Registration timing: **prospective**

Last update: **2022-11-06, 1401/08/15**

Update count: **0**

Registration date

2022-11-06, 1401/08/15

Registrant information

Name

Asieh Maghami Mehr

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 0000 0000

Email address

asimaghami@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-11-22, 1401/09/01

Expected recruitment end date

2023-04-20, 1402/01/31

Actual recruitment start date

empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
A comparative study of the effect of two doses of sufentanil continuous infusion on changes in heart rate and blood pressure after laryngoscopy and tracheal intubation.

Public title
The effect of continuous administration of two doses of sufentanil on changes in heart rate and blood pressure after laryngoscopy and tracheal intubation

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
Age range from 18 to 65 years American Society of Anesthesiologists (ASA) I Requires tracheal intubation for general anesthesia Consent to participate in the study

Exclusion criteria:
Having heart failure Having a systolic blood pressure of less than 14 mmHg and diastolic blood pressure of 9 mmHg Having respiratory, liver, kidney failure Having airway malformations having an addiction

Age
From **18 years** old to **65 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size
Target sample size: **90**

Randomization (investigator's opinion)
Randomized

Randomization description
Before starting the study, letter A is written on 30 sheets, letter B is written on 30 sheets, and letter C is written on 30 sheets and each is placed in an envelope. Then, each eligible patient who consented to participate in the study is asked to choose an envelope from among the envelopes. In this way, the patient will be randomly assigned to one of the three groups according to the envelope selected without the interference of the researcher.

Blinding (investigator's opinion)
Triple blinded

Blinding description
In order to achieve the triple-blind study, different doses of sufentanil and placebo will be prepared daily by the operating room nurse (without the researcher's

awareness) and placed in the bag and will be labeled A, B, and C. And is given daily to the anesthesiologist (researcher). Therefore, the patient, the Investigator, the person recording the clinical and basic information of the patients as well as the statistical analyst will not be aware of the type of intervention.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Isfahan University of Medical Sciences

Street address

Street address Isfahan University of Medical Sciences, Hezar Jarib Ave., Azadi Sq

City

Isfahan

Province

Isfahan

Postal code

8179964167

Approval date

2022-02-20, 1400/12/01

Ethics committee reference number

IR.MUI.MED.REC.1400.816

Health conditions studied

1

Description of health condition studied

Patients requiring tracheal intubation for general anesthesia

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Systolic blood pressure

Timepoint

Baseline time, before laryngoscopy, 1, 3, 10 minutes after laryngoscopy

Method of measurement

Ventilation device

2

Description

Diastolic blood pressure

Timepoint

Baseline time, before laryngoscopy, 1, 3, 10 minutes after laryngoscopy

Method of measurement

Ventilation device

3

Description

Heart beat

Timepoint

Baseline time, before laryngoscopy, 1, 3, 10 minutes after laryngoscopy

Method of measurement

Ventilation device

4

Description

Oxygen saturation (SPO2)

Timepoint

Baseline time, before laryngoscopy, 1, 3, 10 minutes after laryngoscopy

Method of measurement

Ventilation device

Secondary outcomes

empty

Intervention groups

1

Description

First Intervention group: In this group, anesthesia is induced within 60 seconds using sodium thiopental 5 mg/kg, lidocaine 1.5 mg/kg, atracurium 0.6 mg/kg, and sufentanil with a dose of 0.1 µg/kg.

Category

Treatment - Drugs

2

Description

The second intervention group: in this group, in addition to the drugs of the first group, sufentanil is infused at a dose of 0.2 µg/kg within 60 seconds.

Category

Treatment - Drugs

3

Description

Control group: In this group, in addition to the drugs of the first group, normal saline is prescribed instead of sufentanil.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-Zahra Hospital

Full name of responsible person

Azim Honarmand

Street address

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

honarmand@med.mui.a.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Gholamreza Askari

Street address

Vice Chancellor for Research, School of Medicine, Hezar Jarib Street, Isfahan.

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 8597

Email

dean@med.mui.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Isfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Azim Honarmand

Position

Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

honarmand@med.mui.a.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Azim Honarmand

Position

Professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Anesthesiology Department, Al-Zahra Hospita, Sefeh Blvd., Tohid Street

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Email

honarmand@med.mui.a.ir

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Arefeh Ahmadi

Position

Non-faculty specialist doctor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Iran

City

Isfahan

Province

Isfahan

Postal code

Isfahan

Phone

+98 913 815 0992

Email

arefeahmadi875@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information"

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available